Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878532 | 0.81 | FFAR2 (0.38) | CYP1A2CYP3A4CYP2D6MAPTNPC1 | |
| SCHEMBL15319021 | 0.79 | MAPT (0.35) | CYP1A2CYP3A4CYP2D6MAPTNPC1 | |
| SCHEMBL1705826 | 0.79 | LOXL2 (0.36) | CYP1A2CYP3A4CYP2D6MAPTNPC1 | |
| SCHEMBL15319070 | 0.78 | SLC6A3 (0.35) | CYP1A2CYP3A4CYP2D6MAPTNPC1 | |
| SCHEMBL12359889 | 0.77 | MEN1 (0.37) | MAPT | |
| SCHEMBL21854503 | 0.77 | PTGS1 (0.31) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15319143 | 0.77 | ALB (0.35) | CYP1A2CYP3A4CYP2D6RAB9A | |
| SCHEMBL13412427 | 0.74 | CYP1A2 (0.33) | CYP1A2CYP3A4CYP2D6NPC1RAB9A | |
| SCHEMBL15319180 | 0.73 | MAPT (0.46) | CYP1A2CYP3A4MAPTNPC1RAB9A | |
| SCHEMBL5637413 | 0.72 | CYP1A2 (0.45) | CYP1A2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | CYP1A2 2345/4885CYP3A4 3543/4885CYP2D6 2024/4885 |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | CYP1A2 540/4885CYP3A4 1653/4885CYP2D6 1621/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | CYP1A2 1931/4885CYP3A4 3343/4885CYP2D6 2006/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | CYP1A2 746/4885CYP3A4 1407/4885CYP2D6 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.